#China #Shanghai #Henlius #Serplulimab #ES-SCLC

Positive Outcomes from the ASTRIDE Study

On October 26, 2026, Shanghai Henlius Biotech, Inc., a leading biopharmaceutical company known for its innovative approaches, announced the promising results from its ASTRIDE study. This trial involved patients struggling with extensive-stage small cell lung cancer (ES-SCLC). Conducted in the United States, the study compared the efficacy of serplulimab—a PD-1 monoclonal antibody—paired with traditional chemotherapy against atezolizumab, which is widely practiced in the U.S. chemotherapy protocols.

Significance of the ASTRIDE Study

The ASTRIDE trial is a pivotal moment for cancer treatments in the U.S., focusing on patients with ES-SCLC, a highly aggressive form of lung cancer. The trial enrolled over 200 patients across 63 sites, aiming to determine whether serplulimab could offer improved overall survival compared to atezolizumab. The results, which were presented at the European Society for Medical Oncology (ESMO) Congress 2026, reveal that the median overall survival for patients receiving serplulimab was notably longer than for those receiving atezolizumab, marking a significant step in treating this lethal disease.

Key Findings

According to the data cutoff on February 18, 2026, the trial demonstrated a median overall survival of 12.4 months for serplulimab, compared to 10.2 months for atezolizumab (hazard ratio 0.82). The one-year survival rates were 52.4% for serplulimab versus 41.4% for atezolizumab, while the two-year rates stood at 32.2% and 17.6%, respectively. Dr. David R. Gandara, the lead investigator from the University of California Davis, emphasized the importance of these findings in providing a clinical context for serplulimab regarding the U.S. patient demographic.

Supporting Evidence from ASTRUM-005

The findings from ASTRIDE are further corroborated by the ASTRUM-005 trial, which explored the same treatment's efficacy on a global scale. The consistency between these studies is reassuring, particularly for treating underrepresented populations. Notably, the ASTRIDE trial included diverse racially and ethnically diverse cohorts, further emphasizing Henlius's commitment to inclusivity and comprehensive healthcare initiatives.

The Role of Serplulimab

Serplulimab, also recognized by its European name Hetronifly®, has already seen approval across more than 50 countries for treating ES-SCLC and other malignancies. Dr. Jason Zhu, CEO of Henlius, expressed hope regarding the recent trail results, citing an increasing demand for effective treatments in the U.S. market, especially for serplulimab as an option for patients confronted with this aggressive illness.

Closing Remarks

The results from the ASTRIDE trial mark a substantial advancement in the fight against ES-SCLC, presenting a hopeful horizon for patients seeking effective treatment alternatives. As Henlius continues its work in pioneering biopharmaceutical solutions, the healthcare community eagerly watches for further developments on serplulimab's application in broader therapeutic settings.